Navigation Links
Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment

SAN DIEGO, Nov. 18 /PRNewswire-FirstCall/ -- Entest BioMedical Inc. (OTC Bulletin Board: ENTB) announced today the filing of a third patent application relating to the area of chronic obstructive pulmonary disease (COPD), a condition that affects more than 5 million patients in the United States, resulting in more than 120,000 deaths per year. The application covers an implantable medical device useful in re-directing the immune system to stop tissue inflammation.

"The importance of the inflammatory process in COPD is exemplified by the use of broad-acting steroids that reduce inflammation. Unfortunately, these drugs do not address the cause of the inflammation, and have a variety of adverse effects," stated Dr. Stephen Josephs, inventor of the technology.

A recent article "Immunologic aspects of chronic obstructive pulmonary disease" by Cosio et al in the June 4th, 2009 issue of New England Medical Journal suggests that COPD may actually be not just a disease of inflammation but, of active immunological attack. The current technology seeks to induce a process in which immunity towards components of the body is blocked.

"To date Entest has filed two previous patent applications covering use of fat stem cell components in COPD and methods of using photoceuticals to enhance stem cell therapy. The current patent application has a variety of derivative uses outside of COPD including treatment of transplantation rejection, and other disease in which the immune system has gone awry," stated David Koos, Entest's CEO.

The essence of the technology is the use of existing implantable devices to deliver chemical/protein signals that specifically stop inflammatory reactions in a manner that is more in tune with biological processes. Instead of us "telling the body" what it should do with a blunt-force approach, as is the standard of care, the current invention uses more natural and slow acting interventions.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTC Bulletin Board: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTC Bulletin Board: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).


This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


    David R. Koos, Chairman & CEO
    619.702.1404 Direct
    619.330.2328 Fax

    Entest BioMedical Inc.

SOURCE Entest BioMedical Inc.

SOURCE Entest BioMedical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Adipose-derived Stem Cells Could Help Traumatic Brain Injury Patients, Says Bio-Matrix Scientific Groups, Entest BioMedical Inc. Researcher
2. Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury
3. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
4. 40 Years on the Leading Edge: Case Western Reserve Universitys Biomedical Engineering Department Commemorates Achievement, Looks to Future
5. Healthnostics Unveils Biomedical Content Strategy for
6. Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities
7. Biomedical Research Organization Launches Groundbreaking National TV Campaign
8. Nova Biomedical and CCS Medical Reach Definitive Agreement for a Subsidiary of Nova Biomedical to Acquire Assets of CCS Medicals Subsidiary, Sanvita Inc.
9. Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research
10. Environmental Tectonics Corporations BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber
11. ETC Biomedical Announces Chamber Sale in India
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
(Date:6/23/2016)... FRANCISCO , June 22, 2016  Amgen (NASDAQ: ... sponsorship of the QB3@953 life sciences incubator ... human health. The shared laboratory space at QB3@953 was ... overcome a key obstacle for many early stage organizations ... part of the sponsorship, Amgen launched two "Amgen Golden ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):